Peginterferon alfa-2b and ribavirin combination therapy for chronic hepatitis C

Author： Yeh Frank   Gordon Fredric D  

Publisher： Future Medicine

ISSN： 1746-0794

Source： Future Virology, Vol.2, Iss.6, 2007-11, pp. : 553-563

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Peginterferon -2a Plus Ribavirin versus Interferon -2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C

By Sullivan S.D.  

PharmacoEconomics, Vol. 22, Iss. 4, 2004-01 ,pp. : 257-265

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Peginterferon -2a Plus Ribavirin versus Interferon -2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C

By Arguedas M.  

PharmacoEconomics, Vol. 22, Iss. 7, 2004-01 ,pp. : 477-479

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Peginterferon -2a Plus Ribavirin versus Interferon -2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C. The Authors' Reply

By Sullivan S.D.  

PharmacoEconomics, Vol. 22, Iss. 7, 2004-01 ,pp. : 478-479

Adis International

Access to resources Recommend Favorite

Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy

By Modi Marlene   Martin Nancy   Heathcote Jenny E   Nieforth Keith   Zeuzem Stefan  

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 12, 2001-12 ,pp. : 2201-2213

Informa Healthcare

Access to resources Recommend Favorite

Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C

By Xu C.   Gupta S.   Krishna G.   Cutler D.   Wirth S.   Galoppo C.   Ciocca M.   Kolz K.   Noviello S.   Sniukiene V.  

European Journal of Clinical Pharmacology, Vol. 69, Iss. 12, 2013-12 ,pp. : 2045-2054

Springer Publishing Company

Access to resources Recommend Favorite